Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib

The majority of breast cancers express the estrogen receptor (ER) and are dependent on estrogen for their growth and survival. Endocrine therapy (ET) is the standard of care for these tumors. However, a superior outcome is achieved in a subset of ER positive (ER(+))/human epidermal growth factor rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorito, Nicla, Bacci, Marina, Smiriglia, Alfredo, Mannelli, Michele, Parri, Matteo, Comito, Giuseppina, Ippolito, Luigi, Giannoni, Elisa, Bonechi, Martina, Benelli, Matteo, Migliaccio, Ilenia, Malorni, Luca, Chiarugi, Paola, Morandi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140692/
https://www.ncbi.nlm.nih.gov/pubmed/32164162
http://dx.doi.org/10.3390/cells9030668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140692/
https://www.ncbi.nlm.nih.gov/pubmed/32164162
http://dx.doi.org/10.3390/cells9030668

Ejemplares similares